168 related articles for article (PubMed ID: 10430112)
1. Renal effects of selective cyclooxygenase-2 inhibition in normotensive salt-depleted subjects.
Rossat J; Maillard M; Nussberger J; Brunner HR; Burnier M
Clin Pharmacol Ther; 1999 Jul; 66(1):76-84. PubMed ID: 10430112
[TBL] [Abstract][Full Text] [Related]
2. Comparison of rofecoxib, celecoxib, and naproxen on renal function in elderly subjects receiving a normal-salt diet.
Schwartz JI; Vandormael K; Malice MP; Kalyani RN; Lasseter KC; Holmes GB; Gertz BJ; Gottesdiener KM; Laurenzi M; Redfern KJ; Brune K
Clin Pharmacol Ther; 2002 Jul; 72(1):50-61. PubMed ID: 12152004
[TBL] [Abstract][Full Text] [Related]
3. Effects of celecoxib and diclofenac on blood pressure, renal function, and vasoactive prostanoids in young and elderly subjects.
Dilger K; Herrlinger C; Peters J; Seyberth HW; Schweer H; Klotz U
J Clin Pharmacol; 2002 Sep; 42(9):985-94. PubMed ID: 12211224
[TBL] [Abstract][Full Text] [Related]
4. Renal effects of the cyclooxygenase-inhibiting nitric oxide donator AZD3582 compared with rofecoxib and naproxen during normal and low sodium intake.
Huledal G; Jonzon B; Malmenäs M; Hedman A; Andersson LI; Odlind B; Brater DC
Clin Pharmacol Ther; 2005 May; 77(5):437-50. PubMed ID: 15900289
[TBL] [Abstract][Full Text] [Related]
5. Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids.
Catella-Lawson F; McAdam B; Morrison BW; Kapoor S; Kujubu D; Antes L; Lasseter KC; Quan H; Gertz BJ; FitzGerald GA
J Pharmacol Exp Ther; 1999 May; 289(2):735-41. PubMed ID: 10215647
[TBL] [Abstract][Full Text] [Related]
6. Treatment of painful temporomandibular joints with a cyclooxygenase-2 inhibitor: a randomized placebo-controlled comparison of celecoxib to naproxen.
Ta LE; Dionne RA
Pain; 2004 Sep; 111(1-2):13-21. PubMed ID: 15327804
[TBL] [Abstract][Full Text] [Related]
7. Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: a randomized controlled trial.
Bensen WG; Fiechtner JJ; McMillen JI; Zhao WW; Yu SS; Woods EM; Hubbard RC; Isakson PC; Verburg KM; Geis GS
Mayo Clin Proc; 1999 Nov; 74(11):1095-105. PubMed ID: 10560596
[TBL] [Abstract][Full Text] [Related]
8. Renal functional responses to ischaemia-reperfusion injury in normotensive and hypertensive rats following non-selective and selective cyclo-oxygenase inhibition with nitric oxide donation.
Knight S; Johns EJ
Clin Exp Pharmacol Physiol; 2008 Jan; 35(1):11-6. PubMed ID: 18047621
[TBL] [Abstract][Full Text] [Related]
9. Effects of celecoxib and naproxen on renal function in nonazotemic patients with cirrhosis and ascites.
Clària J; Kent JD; López-Parra M; Escolar G; Ruiz-Del-Arbol L; Ginès P; Jiménez W; Vucelic B; Arroyo V
Hepatology; 2005 Mar; 41(3):579-87. PubMed ID: 15723448
[TBL] [Abstract][Full Text] [Related]
10. Upper gastrointestinal tolerability of celecoxib, a COX-2 specific inhibitor, compared to naproxen and placebo.
Bensen WG; Zhao SZ; Burke TA; Zabinski RA; Makuch RW; Maurath CJ; Agrawal NM; Geis GS
J Rheumatol; 2000 Aug; 27(8):1876-83. PubMed ID: 10955327
[TBL] [Abstract][Full Text] [Related]
11. Differential effects of selective cyclooxygenase-2 inhibitors on endothelial function in salt-induced hypertension.
Hermann M; Camici G; Fratton A; Hurlimann D; Tanner FC; Hellermann JP; Fiedler M; Thiery J; Neidhart M; Gay RE; Gay S; Lüscher TF; Ruschitzka F
Circulation; 2003 Nov; 108(19):2308-11. PubMed ID: 14597594
[TBL] [Abstract][Full Text] [Related]
12. Celecoxib in the treatment of primary dysmenorrhea: results from two randomized, double-blind, active- and placebo-controlled, crossover studies.
Daniels S; Robbins J; West CR; Nemeth MA
Clin Ther; 2009 Jun; 31(6):1192-208. PubMed ID: 19695387
[TBL] [Abstract][Full Text] [Related]
13. COX-2-specific inhibitors and the kidney: effect on hypertension and oedema.
Whelton A
J Hypertens Suppl; 2002 Sep; 20(6):S31-5. PubMed ID: 12683425
[TBL] [Abstract][Full Text] [Related]
14. Chemopreventive properties of a selective inducible nitric oxide synthase inhibitor in colon carcinogenesis, administered alone or in combination with celecoxib, a selective cyclooxygenase-2 inhibitor.
Rao CV; Indranie C; Simi B; Manning PT; Connor JR; Reddy BS
Cancer Res; 2002 Jan; 62(1):165-70. PubMed ID: 11782374
[TBL] [Abstract][Full Text] [Related]
15. Renal effects on a solitary kidney of specific inhibition of cyclooxygenease-2 after 24 h of complete ureteric obstruction in rats.
Oztürk H; Ozdemir E; Otcu S; Büyükbayram H; Ihsan Dokucu A
Urol Res; 2002 Sep; 30(4):223-6. PubMed ID: 12202939
[TBL] [Abstract][Full Text] [Related]
16. Outcome of specific COX-2 inhibition in rheumatoid arthritis.
Lipsky PE; Isakson PC
J Rheumatol Suppl; 1997 Jul; 49():9-14. PubMed ID: 9249645
[TBL] [Abstract][Full Text] [Related]
17. Effect of nonsteroidal anti-inflammatory drugs with varying extent of COX-2-COX-1 selectivity on urinary sodium and potassium excretion in the rat.
Harirforoosh S; Jamali F
Can J Physiol Pharmacol; 2005 Jan; 83(1):85-90. PubMed ID: 15759054
[TBL] [Abstract][Full Text] [Related]
18. Wound collagen deposition in rats: effects of an NO-NSAID and a selective COX-2 inhibitor.
Muscará MN; McKnight W; Asfaha S; Wallace JL
Br J Pharmacol; 2000 Feb; 129(4):681-6. PubMed ID: 10683192
[TBL] [Abstract][Full Text] [Related]
19. In vivo selectivity of a selective cyclooxygenase 2 inhibitor in the oral surgery model.
Khan AA; Brahim JS; Rowan JS; Dionne RA
Clin Pharmacol Ther; 2002 Jul; 72(1):44-9. PubMed ID: 12152003
[TBL] [Abstract][Full Text] [Related]
20. Celecoxib does not alter cardiovascular and renal function during dietary salt loading.
Wenner MM; Edwards DG; Ray CA; Rose WC; Gardner TJ; Stillabower M; Farquhar WB
Clin Exp Pharmacol Physiol; 2011 Aug; 38(8):543-9. PubMed ID: 21631568
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
